In 2015, CIRM launched an ambitious Strategic Plan built around six major goals. Together, they aimed to accelerate the development of stem cell and regenerative medicine therapies for patients with unmet medical needs.
One goal focused on a simple but critical challenge: speeding up the path from discovery to clinical testing.
The goal was called Accelerate.
A Bold Goal to Move Therapies Faster
Developing a new therapy takes time.
On average, it can take more than a decade for a treatment to move from early research to FDA approval. Stem cell therapies often face an even longer journey.
Many factors contribute to those timelines. Safety testing, manufacturing requirements, and regulatory reviews all play essential roles.
CIRM recognized those realities but also saw opportunities to improve the process.
In 2015, it took roughly eight years for a CIRM-supported therapy candidate to progress from early development to an Investigational New Drug (IND) application. An IND allows researchers to begin FDA-authorized clinical trials.
Rather than accepting that timeline, CIRM set an ambitious target.
The agency aimed to cut the process in half, reducing the average timeline from eight years to four.
Building the Infrastructure to Accelerate Research
Before developing the Strategic Plan, CIRM met with researchers across California.
Scientists at institutions such as UCLA, UC San Francisco, Stanford, and others shared a common concern.
Many promising discoveries stalled because researchers lacked the expertise, partnerships, or resources needed to advance projects into later stages of development.
Researchers repeatedly asked for a way to connect early-stage discoveries with experienced translational and clinical development partners.
CIRM responded by creating programs that helped investigators build those connections and navigate the development pipeline more efficiently.
The agency also introduced Clinical Advisory Panels (CAPs).
Each panel brought together:
- A CIRM Science Officer
- A scientific expert in the relevant field
- A patient representative
These panels worked directly with research teams to identify challenges, provide guidance, and help projects move toward clinical testing.
The patient representatives played a particularly important role. They helped researchers understand the needs and priorities of the communities they hoped to serve.
This collaborative approach allowed CIRM to do more than provide funding.
The agency actively supported teams as they advanced therapies through the development process.
Measuring Success
The results show that the strategy worked.
For translational-stage projects, the average time needed to advance to the CLIN1 stage, the final phase before clinical testing, fell to approximately 4.18 years.
That outcome came remarkably close to CIRM’s original goal.
The agency also saw strong performance among projects already approaching the clinic.
Seventy-three percent of CLIN1 programs achieved IND approval within two years.
That milestone allowed those programs to move into FDA-authorized clinical trials and continue their path toward patients.
These results demonstrate that strategic support, experienced guidance, and strong partnerships can help accelerate development without compromising scientific rigor or patient safety.
Measuring Success Through Patient Impact
Speed alone does not guarantee that a therapy will succeed.
Every potential treatment must still demonstrate safety and effectiveness through rigorous testing.
Some therapies will ultimately fail. Others will advance and transform patient care.
The goal of acceleration is not to cut corners.
The goal is to remove unnecessary barriers that delay progress.
For patients living with serious diseases, time matters.
Every year saved in development creates opportunities to bring promising therapies to people who have few or no treatment options.
Looking Ahead
The success of the Accelerate initiative helped shape CIRM’s next Strategic Plan and reinforced an important lesson.
Innovation requires more than funding.
Researchers also need mentorship, expertise, collaboration, and support throughout the development journey.
By creating programs that connect scientists, clinicians, industry partners, and patients, CIRM helped shorten the path from discovery to clinical testing.
Those efforts continue to advance the agency’s mission: accelerating world-class science to deliver transformative treatments to patients who need them most.
